BV-CHP treatment in real-life for sALCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at real-world data and biological samples from people with systemic anaplastic large cell lymphoma (sALCL) who received BV-CHP as their first treatment. The goal is to learn more about how this treatment works and find clues that might help predict outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with a type of lymphoma called systemic anaplastic large cell lymphoma (sALCL), whether it is ALK positive or ALK negative.
- Your first treatment for this lymphoma was the combination BV-CHP (brentuximab vedotin, cyclophosphamide, doxorubicin, prednisone).
- You have a stored biopsy sample (a wax block) from your initial diagnosis that can be used for testing.
- You agree to sign a consent form to participate in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at real-world experiences of people with chronic lymphocytic leukemia (CLL) who have used or are using a type of targeted therapy called a BCL-2 inhibitor. It aims to understand how well these treatments work and their side effects in everyday practice.
This Phase 3 trial studies an early treatment approach for people with high-risk CLL or SLL who have not yet needed standard therapy. It aims to see if treating earlier can improve outcomes while keeping side effects manageable.
This study looks at the biology of certain lymphomas to better understand why some people respond well to treatment and others don't. It involves giving a small additional blood or tissue sample to help researchers find genetic clues that could improve future care.
This study looks back at the health records of people who were treated for BPDCN (a rare blood cancer) with chemotherapy as their first treatment. The goal is to learn more about how the disease progresses and how well treatments work in the real world. If you meet the criteria, your past medical data may be included.
This trial uses a blood test (ctDNA) and PET scans to predict how well standard first-line treatment works for diffuse large B-cell lymphoma (DLBCL). It aims to find out if these tests can guide better care.
This study collects information and samples from people with large B-cell lymphoma who are either too frail for standard chemo, or whose disease has come back after one prior treatment. The goal is to better understand how to treat these situations.
Hear when a new Anaplastic Large Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.